These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38230393)

  • 21. Correlation between changes of pelvic bone marrow fat content and hematological toxicity in concurrent chemoradiotherapy for cervical cancer.
    Wang C; Qin X; Gong G; Wang L; Su Y; Yin Y
    Radiat Oncol; 2022 Apr; 17(1):70. PubMed ID: 35392934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of Acute Hematologic Toxicity in Women Receiving Extended-Field Chemoradiation for Cervical Cancer: Do Known Pelvic Radiation Bone Marrow Constraints Apply?
    Hara JHL; Jutzy JMS; Arya R; Kothari R; McCall AR; Howard AR; Hasan Y; Cursio JF; Son CH
    Adv Radiat Oncol; 2022; 7(6):100998. PubMed ID: 36420189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of radiotherapy time and dose on acute hematologic toxicity during concurrent postoperative chemoradiotherapy for early high-risk cervical cancer.
    Yang X; Li Z; Zhang L; Li H; Yang X; Sun Y; Liu L; Fu J
    J Cancer; 2023; 14(6):895-902. PubMed ID: 37151393
    [No Abstract]   [Full Text] [Related]  

  • 24. The relationship between the radiation dose of pelvic-bone marrow and lymphocytic toxicity in concurrent chemoradiotherapy for cervical cancer.
    Zhang BZ; Li Y; Xu LM; Chai YL; Qu C; Cao YJ; Wang J; Hou HL; Zhang J
    Radiat Oncol; 2023 Jan; 18(1):12. PubMed ID: 36658595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 26. Dosimetric predictors and Lyman normal tissue complication probability model of hematological toxicity in cervical cancer patients with treated with pelvic irradiation.
    Wang D; Yin Y; Zhou Q; Li Z; Ma X; Yin Y; Li B; Bai T; Li D; Zhu J
    Med Phys; 2022 Jan; 49(1):756-767. PubMed ID: 34800297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Chemotherapy Regimens on Normal Tissue Complication Probability Models of Acute Hematologic Toxicity in Rectal Cancer Patients Receiving Intensity Modulated Radiation Therapy With Concurrent Chemotherapy From a Prospective Phase III Clinical Trial.
    Cheng Y; Ma Y; Zheng J; Deng H; Wang X; Li Y; Pang X; Chen H; He F; Wang L; Wang J; Wan X
    Front Oncol; 2019; 9():244. PubMed ID: 31024846
    [No Abstract]   [Full Text] [Related]  

  • 28. A prospective single-arm study on the relationship between dose-volume parameters of pelvic functional bone marrow and acute hematological toxicities during intensity-modulated radiotherapy with or without concurrent chemotherapy for uterine cervical/endometrial cancer.
    Chen H; Zhong Q; Liu Y; Li J; Deng W; Wang J; Zhou S; Yu Z; Huang X; Huang Y; Zhen B; Wei J; Zhang W; Ruan X; Xiao L
    Radiat Oncol; 2023 Nov; 18(1):193. PubMed ID: 38012675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 30. Thrombocytopenia after liver transplantation.
    Chatzipetrou MA; Tsaroucha AK; Weppler D; Pappas PA; Kenyon NS; Nery JR; Khan MF; Kato T; Pinna AD; O'Brien C; Viciana A; Ricordi C; Tzakis AG
    Transplantation; 1999 Mar; 67(5):702-6. PubMed ID: 10096525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.
    Wang SL; Liao Z; Vaporciyan AA; Tucker SL; Liu H; Wei X; Swisher S; Ajani JA; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):692-9. PubMed ID: 16242257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC.
    Chang Y; Yang ZY; Li GL; Li Q; Yang Q; Fan JQ; Zhao YC; Song YQ; Wu G
    Int J Gynecol Cancer; 2016 May; 26(4):770-6. PubMed ID: 26844613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer.
    Deek MP; Benenati B; Kim S; Chen T; Ahmed I; Zou W; Aisner J; Jabbour SK
    Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):147-154. PubMed ID: 26700708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone marrow dosimetric analysis of lymphopenia in patients with esophageal squamous cell carcinoma treated with chemoradiotherapy.
    Wang Q; Qiu Q; Zhang Z; Zhang J; Yang G; Liu C; Li B
    Cancer Med; 2021 Sep; 10(17):5847-5858. PubMed ID: 34363346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy.
    Hui B; Zhang Y; Shi F; Wang J; Wang T; Wang J; Yuan W; Li Y; Liu Z
    Int J Gynecol Cancer; 2014 Nov; 24(9):1648-52. PubMed ID: 25275663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between dose-volume parameters and acute bone marrow suppression in rectal cancer patients treated with concurrent chemoradiotherapy.
    Li N; Liu X; Zhai F; Liu B; Cao X; Li S; Zhang M; Liu M
    Oncotarget; 2017 Nov; 8(54):92904-92913. PubMed ID: 29190965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dosimetric analysis of lymphopenia during chemoradiotherapy for esophageal cancer.
    Newman NB; Anderson JL; Sherry AD; Osmundson EC
    J Thorac Dis; 2020 May; 12(5):2395-2405. PubMed ID: 32642145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spleen Dose-Volume Parameters as a Predictor of Treatment-related Lymphopenia During Definitive Chemoradiotherapy for Esophageal Cancer.
    Saito T; Toya R; Yoshida N; Shono T; Matsuyama T; Ninomura S; Watakabe T; Sasaki Y; Baba H; Oya N
    In Vivo; 2018; 32(6):1519-1525. PubMed ID: 30348711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical features and prognosis of anastomotic leak after anterior resection for rectal cancer following neoadjuvant chemoradiotherapy].
    Qin QY; Wu YL; Cai YH; Kuang YY; He YJ; Huang XY; Wang H; Ma TH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Jun; 24(6):513-522. PubMed ID: 34148316
    [No Abstract]   [Full Text] [Related]  

  • 40. Preoperative chemoradiation-induced hematological toxicity and related vertebral dosimetry evaluations in patients with locally advanced gastric cancer: data from a phase III clinical trial.
    Wang JJ; Shao H; Zhang L; Jing M; Xu WJ; Sun HW; Zhou ZW; Zhang YJ
    Radiat Oncol; 2023 Jun; 18(1):100. PubMed ID: 37365597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.